OTCPK:HPHW.Q

Stock Analysis Report

Executive Summary

Hooper Holmes, Inc. provides health and wellness services in the United States.

Snowflake

Fundamentals

Mediocre balance sheet and slightly overvalued.

Risks

  • Hooper Holmes has significant price volatility in the past 3 months.
  • Hooper Holmes is not covered by any analysts.

Share Price & News

How has Hooper Holmes's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:HPHW.Q

0.8%

US Healthcare

1.3%

US Market


1 Year Return

-99.7%

OTCPK:HPHW.Q

-8.2%

US Healthcare

2.0%

US Market

HPHW.Q underperformed the Healthcare industry which returned 2.8% over the past year.

HPHW.Q underperformed the Market in United States of America which returned -7% over the past year.


Share holder returns

HPHW.QIndustryMarket
7 Day0%0.8%1.3%
30 Day25.0%-1.5%3.9%
90 Day-72.7%-0.5%3.4%
1 Year-99.7%-99.7%-6.8%-8.2%4.2%2.0%
3 Year-99.9%-99.9%30.2%24.9%47.2%37.6%
5 Year-100.0%-100.0%63.6%53.9%60.5%42.9%

Price Volatility Vs. Market

How volatile is Hooper Holmes's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Hooper Holmes undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Hooper Holmes's share price is below the future cash flow value, and at a moderate discount (> 20%).

Hooper Holmes's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Hooper Holmes is loss making, we can't compare its value to the US Healthcare industry average.

Hooper Holmes is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Hooper Holmes, we can't assess if its growth is good value.


Price Based on Value of Assets

Hooper Holmes has negative assets, we can't compare the value of its assets to the US Healthcare industry average.


Next Steps

Future Growth

How is Hooper Holmes expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Hooper Holmes has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of HPHW.Q’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Hooper Holmes's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Hooper Holmes performed over the past 5 years?

-12.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Hooper Holmes does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Hooper Holmes's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Hooper Holmes's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Hooper Holmes has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Hooper Holmes has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Hooper Holmes improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is Hooper Holmes's financial position?


Financial Position Analysis

Hooper Holmes's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Hooper Holmes's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Hooper Holmes has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Hooper Holmes's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Hooper Holmes has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Hooper Holmes has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Hooper Holmes has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -104.8% per year.


Next Steps

Dividend

What is Hooper Holmes's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Hooper Holmes's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Hooper Holmes's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Hooper Holmes has not reported any payouts.

Unable to verify if Hooper Holmes's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Hooper Holmes has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Hooper Holmes's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Jim Fleet (56yo)

0.8yrs

Tenure

0

Mr. James E. Fleet, also known as Jim, has been Chief Restructuring Officer and Interim Chief Executive Officer of Hooper Holmes, Inc. since March 26, 2018 and May 27, 2018 respectively. Mr. Fleet serves a ...


Management Age and Tenure

1.3yrs

Average Tenure

The average tenure for the Hooper Holmes management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.4yrs

Average Tenure

60yo

Average Age

The tenure for the Hooper Holmes board of directors is about average.


Insider Trading

Hooper Holmes insiders have only sold shares in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

SellUS$18014 Dec 18
Paul Daoust
EntityIndividual
Role
Member of the Board of Directors
Director
Shares100,000
Max PriceUS$0.0018

Ownership Breakdown


Management Team

  • Jim Fleet (56yo)

    Interim CEO & Chief Restructuring Officer

    • Tenure: 0.8yrs
  • Mike Benton

    Head of UK-Based Medicals Direct

    • Tenure: 0yrs
  • Heather Provino

    Chief Strategy Officer

    • Tenure: 1.8yrs
  • Dave Ashley

    Chief Medical Officer

    • Tenure: 0yrs
  • Mark Clermont (51yo)

    Chief Financial Officer & Treasurer

    • Tenure: 0.3yrs
    • Compensation: US$545.69k
  • Andrew Berger

    Investor Relations

    • Tenure: 9.1yrs
  • Tom Basiliere

    Chief Information Officer

    • Tenure: 1.5yrs
    • Compensation: US$407.88k
  • Marc Salois

    Chief Revenue Officer

    • Tenure: 1.1yrs
  • Elaine Peterson

    Senior Director of Marketing & Communications

    • Tenure: 0yrs

Board Members

  • Frank Bazos (50yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$86.98k
  • Ron Aprahamian (71yo)

    Chairman of the Board

    • Tenure: 7.1yrs
    • Compensation: US$131.68k
  • Larry Ferguson (68yo)

    Director

    • Tenure: 9.8yrs
    • Compensation: US$116.68k
  • Jim Foreman (60yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$90.73k
  • Paul Daoust (70yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$86.98k
  • Tom Watford (58yo)

    Director

    • Tenure: 8.2yrs
    • Compensation: US$121.68k
  • Jim Foreman (60yo)

    • Tenure: 0yrs
  • Jim Foreman (60yo)

    • Tenure: 0yrs

Company Information

Hooper Holmes, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Hooper Holmes, Inc.
  • Ticker: HPHW.Q
  • Exchange: OTCPK
  • Founded: 1899
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$40.152k
  • Shares outstanding: 26.77m
  • Website: https://www.provanthealth.com

Number of Employees


Location

  • Hooper Holmes, Inc.
  • 560 North Rogers Road
  • Olathe
  • Kansas
  • 66062
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HPHW.QOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJul 1984

Biography

Hooper Holmes, Inc. provides health and wellness services in the United States. The company offers on-site screenings and flu shots, laboratory testing, risk assessment, and sample collection services to i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/02/01 01:06
End of Day Share Price2019/01/29 00:00
Earnings2018/06/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.